Rapid Micro Biosystems, Inc. SEC Filings

Rapid Micro Biosystems, Inc. (RPID) director Kirk Malloy reported a charitable gift of 40,000 shares of the company’s Class A common stock on 11/14/2025. The transaction was coded as a gift at a reported price of $0, reflecting that it was a non-sale transfer to a non-profit charitable organization.

After this transaction, Malloy beneficially owns 28,600 shares directly and an additional 10,000 shares indirectly through a family trust in which he shares investment power and where he and/or immediate family members are beneficiaries.

Rapid Micro Biosystems (RPID) reported Q3 2025 results and added new debt capacity. Revenue was $7.8 million, essentially flat year over year ($7.6 million). Product revenue was $5.2 million and service revenue $2.6 million. The company recorded a net loss of $11.5 million, similar to the prior year’s $11.3 million, as operating expenses and cost of sales remained elevated.

For the first nine months, revenue rose to $22.3 million from $19.8 million, while net loss narrowed to $34.6 million from $37.2 million. Cash and cash equivalents were $18.9 million and short‑term investments $22.3 million as of September 30, 2025. Deferred revenue stood at $5.1 million, supporting future service activity.

On August 8, 2025, the company entered a loan and security agreement of up to $45.0 million with Trinity Capital, drawing $20.0 million initially at a minimum interest rate of 11.0% (initially 11.5%). In connection, RPID issued warrants for 179,104 Class A shares at a $3.35 exercise price; a warrant liability of $0.36 million was recorded. Operating cash outflow was $27.8 million for the nine‑month period. As of October 31, 2025, Class A shares outstanding were 39,823,026 and Class B were 4,499,529.

Rapid Micro Biosystems (RPID) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference.

The information under Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. The filing also includes Exhibit 104 for the cover page inline XBRL.

Rapid Micro Biosystems (RPID) reported insider transactions by President & CEO and Director Robert G. Spignesi, Jr. on 10/17/2025. He exercised stock options (code M) for 3,400 and 7,833 shares at an exercise price of $0.75 per share via net exercise. The company withheld 2,072 and 4,774 shares (code F) using the $3.08 closing price to cover the exercise price and taxes, consistent with the 2010 Stock Option and Grant Plan. Following these transactions, he directly owned 974,937 Class A common shares.

Robert G. Spignesi Jr., President and CEO of Rapid Micro Biosystems (RPID), reports beneficial ownership of 2,647,256 shares of Class A common stock, representing approximately 6.3% of the outstanding Class A shares. This total includes 493,931 shares held directly, 10 shares issuable upon exercise of warrants within 60 days, and 2,153,315 shares issuable upon exercise of options exercisable within 60 days. He also holds 731,871 restricted stock units subject to vesting and options to purchase 2,619,434 shares at exercise prices between $0.75 and $10.85. The filing discloses recent vesting-related acquisitions of 125,722 shares and open-market sales of 57,443 shares to satisfy tax withholding.

Rapid Micro Biosystems reported total revenue of $7.262 million for the quarter and $14.467 million for the six months ended June 30, 2025, up from $6.618 million and $12.229 million in the comparable prior periods. The company recorded a net loss of $11.858 million for the quarter and $23.121 million year-to-date, narrowing from prior-year losses. Cash and cash equivalents were $18.333 million and short-term investments were $12.922 million, with total current assets of $60.146 million.

The company disclosed a material financing arrangement: a $45.0 million loan facility with Trinity Capital as agent, of which an initial $20.0 million tranche was drawn. Management states existing cash, investments and the initial draw from the facility are expected to fund operations for at least twelve months. The report highlights ongoing operating losses, inventory reserves, concentration among certain customers, and stock-based compensation trends.

Rapid Micro Biosystems secured a multi-tranche term loan facility of up to $45.0 million, drawing $20.0 million at closing. The facility is structured in four tranches with additional amounts available when commercial and operational milestones are met and includes a lender option tranche of $5.0 million. Loans are secured by a first-priority lien on substantially all assets of the company and may be guaranteed by subsidiaries.

Interest is floating with an initial rate of 11.5% per annum (floor 11.0%), a 36-month interest-only period followed by amortization, and a maturity date of September 1, 2030. Fees include a 1.0% commitment fee on amounts drawn, prepayment premiums (3.0% year one, 2.0 year two, 1.0% thereafter), and a 4.0% end-of-term payment on amounts drawn. Each draw requires issuance of warrants equal to 3.0% of the drawn amount (cashless exercise, ten-year term); the company issued warrants for up to 179,104 shares at a $3.35 exercise price for the first tranche. The agreement contains customary covenants and defaults but does not require maintaining specific revenue or cash thresholds.